Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 metronomic chemotherapy trial in relapsed or refractory Wilms tumor
2021-002540-67Phase 2Active
- Sponsor
- Centre Oscar Lambret
- Start
- Nov 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vincristine, irinotecan, temozolomide, etoposide and isotretinoin in Wilms' tumor, sponsored by Centre Oscar Lambret. Primary endpoint: Disease control after 2 cycles of treatment. Started Nov 2021; status: active.
02
Drugs
vincristineirinotecantemozolomideetoposideisotretinoin
03
Conditions
Wilms' tumor
Beyond the preview
Go deeper on 2021-002540-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002540-67.